fluconazole has been researched along with Obesity in 5 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although there are many potential changes of pharmacokinetic parameters in patients with thermal injury, obesity or septicemia, data about the actual effect on pharmacokinetics and clinical efficacy of fluconazole are very limited." | 4.80 | Special pharmacokinetics of fluconazole in septic, obese and burn patients. ( Penk, A; Pittrow, L, 1999) |
| "In our population of obese but otherwise healthy individuals, obesity clearly alters the pharmacokinetics of fluconazole, which puts severely obese adults, particularly if male, at risk of suboptimal exposure, for which adjusted doses are proposed." | 4.12 | Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults. ( Brüggemann, RJ; Chen, L; Knibbe, CAJ; Krekels, EHJ; van der Linden, PD; van Dongen, EPA; van Rhee, KP; Verweij, PE; Wasmann, RE; Wiezer, MJ, 2022) |
| " Herein, we investigate the anti-obesity efficacy of the antifungal antibiotics (amphotericin B, fluconazole and 5-fluorocytosine) in the high fat diet-fed (HFD) mice." | 4.02 | The gut commensal fungus, Candida parapsilosis, promotes high fat-diet induced obesity in mice. ( Chen, W; Dai, H; Hu, X; Li, H; Liu, H; Qiao, S; Sun, L; Sun, S; Wang, K; Zhang, S; Zhao, X, 2021) |
| " Based on currently available data, some antifungals should be dosed based on total body weight (i." | 2.53 | Dosing of antifungal agents in obese people. ( Hall, RG; Payne, KD, 2016) |
| "Fluconazole resistance was highest among C." | 1.91 | Profiling of potential pathogenic candida species in obesity. ( Din, G; Faryal, R; Khadija, B; Shoukat, M; Tariq, MN; Ullah, F, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, S | 1 |
| Sun, L | 1 |
| Wang, K | 1 |
| Qiao, S | 1 |
| Zhao, X | 1 |
| Hu, X | 1 |
| Chen, W | 1 |
| Zhang, S | 1 |
| Li, H | 1 |
| Dai, H | 1 |
| Liu, H | 1 |
| Chen, L | 1 |
| van Rhee, KP | 1 |
| Wasmann, RE | 1 |
| Krekels, EHJ | 1 |
| Wiezer, MJ | 1 |
| van Dongen, EPA | 1 |
| Verweij, PE | 1 |
| van der Linden, PD | 1 |
| Brüggemann, RJ | 1 |
| Knibbe, CAJ | 1 |
| Shoukat, M | 2 |
| Ullah, F | 2 |
| Tariq, MN | 2 |
| Din, G | 2 |
| Khadija, B | 2 |
| Faryal, R | 2 |
| Payne, KD | 1 |
| Hall, RG | 1 |
| Pittrow, L | 1 |
| Penk, A | 1 |
2 reviews available for fluconazole and Obesity
| Article | Year |
|---|---|
Dosing of antifungal agents in obese people.
Topics: Amphotericin B; Antifungal Agents; Candidiasis, Invasive; Caspofungin; Echinocandins; Fluconazole; H | 2016 |
Special pharmacokinetics of fluconazole in septic, obese and burn patients.
Topics: Adult; Antifungal Agents; Burns; Fluconazole; Humans; Male; Mycoses; Obesity; Sepsis | 1999 |
3 other studies available for fluconazole and Obesity
| Article | Year |
|---|---|
The gut commensal fungus, Candida parapsilosis, promotes high fat-diet induced obesity in mice.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida parapsilosis; Diet, High-Fat; Fluconazole; Flucy | 2021 |
Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults.
Topics: Adult; Body Weight; Female; Fluconazole; Humans; Male; Mycoses; Obesity; Prospective Studies | 2022 |
Profiling of potential pathogenic candida species in obesity.
Topics: Antifungal Agents; Candida; Candida albicans; Case-Control Studies; Drug Resistance, Fungal; Flucona | 2023 |
Profiling of potential pathogenic candida species in obesity.
Topics: Antifungal Agents; Candida; Candida albicans; Case-Control Studies; Drug Resistance, Fungal; Flucona | 2023 |
Profiling of potential pathogenic candida species in obesity.
Topics: Antifungal Agents; Candida; Candida albicans; Case-Control Studies; Drug Resistance, Fungal; Flucona | 2023 |
Profiling of potential pathogenic candida species in obesity.
Topics: Antifungal Agents; Candida; Candida albicans; Case-Control Studies; Drug Resistance, Fungal; Flucona | 2023 |